Journal
CELL BIOLOGY INTERNATIONAL
Volume 39, Issue 3, Pages 246-252Publisher
WILEY-BLACKWELL
DOI: 10.1002/cbin.10383
Keywords
arginine deprivation; cancer; metabolic therapy
Categories
Funding
- Polish Ministry of Science and Higher Education [N303318239]
- North Atlantic Treaty Organization [NUKR.SFPP 984173]
- integrated scientific Program of the National Academy of Science of Ukraine Sensors for Medical, Environmental, Industrial, and Technological Needs: Metrological Support and Trial Operation [5/3-2013]
- Innovation project of NAS of Ukraine [41]
Ask authors/readers for more resources
Tumor cells often exhibit specific metabolic defects due to the aberrations in oncogene-dependent regulatory and/or signaling pathways that distinguish them from normal cells. Among others, many malignant cells are deficient in biosynthesis of certain amino acids and concomitantly exhibit elevated sensitivity to deprivation of these amino acids. Although the underlying causes of such metabolic changes are still not fully understood, this feature of malignant cells is exploited in metabolic enzymotherapies based on single amino acid, e.g., arginine, deprivation. To achieve efficient arginine depletion in vivo, two recombinant enzymes, bacterial arginine deiminase and human arginase I have been evaluated and are undergoing further development. This review is aimed to summarize the current knowledge on the application of arginine-degrading enzymes as anticancer agents and as bioanalytical tools for arginine assays. The problems that have to be solved to optimize this therapy for clinical application are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available